Tag: Deep vein thrombosis

Cardiovascular Systems, Inc.

Cardiovascular Systems announces US FDA 510(k) submission of Innova Vascular’s thrombectomy...

Cardiovascular Systems (CSI) announced that Innova Vascular (Innova) has submitted a 510(k) premarket notification to the US Food and Drug Administration (FDA) for its...
mechanical thrombectomy

Mechanical thrombectomy for DVT: Randomised data needed to boost growing evidence...

Two datasets presented during the late-breaking clinical trials session at The VEINS (Venous Endovascular Interventional Strategies) 2022 (30–31 October, Las Vegas, USA)—the latest results...

ClotTriever deemed a “game-changer” in deep vein thrombosis treatment

This advertorial, sponsored by Inari Medical, is only available in selected countries and geographies. “I am finally very confident I have a device that...

Why ClotTriever is a “gamechanger” for the treatment of deep vein...

 Andrew Wigham (Oxford, UK) and Rick De Graaf (Friedrichshafen, Germany) discuss the current state of deep vein thrombosis (DVT) treatment at the Leipzig Interventional...
ClotTriever

Inari Medical announces randomised controlled trial evaluating clinical outcomes of the...

Inari Medical has announced planned enrolment of the DEFIANCE randomised controlled trial (RCT), which is designed to compare the clinical outcomes of patients with...
COVID-19

Study finds increased risk of serious blood clots up to six...

A study from Sweden published by The BMJ recently finds an increased risk of deep vein thrombosis (DVT) up to three months after COVID-19 infection,...
Cordis

Cordis makes strategic investment in E2, a developer of next-generation thrombectomy...

Cordis has announced a strategic investment venture that will expand the scope of the global cardiovascular technology company into the venous thromboembolism (VTE) market...
CardioVascular Systems CSI

Cardiovascular Systems partners with Innova Vascular to develop full line of...

Cardiovascular Systems Inc (CSI) recently announced it has partnered with Innova Vascular (Innova) to develop a full line of novel thrombectomy devices.  According to a...

AVF 2022: Six-month CLOUT data indicate ClotTriever can effectively remove full...

Six-month outcomes from the ongoing CLOUT registry demonstrate the “safety and efficacy” of the ClotTriever thrombectomy system (Inari Medical) in a real-world deep vein...

AVF 2022: Emerging autogenous venous valve formation system sees “continual improvement”

An emerging endovenous valve formation system designed to treat patients with chronic venous insufficiency (CVI) with evidence of deep venous reflux has demonstrated continual...
mercator

NIH grant sets Mercator research underway for local anti-inflammatory DVT therapy

Mercator MedSystems has recently announced that the DEXTERITY trials research has begun under a technology transfer grant for approximately $300,000 funded by the National...
Sue gala talks about patients treat with PCDT

ATTRACT analysis finds improved quality of life for iliofemoral DVT patients...

An analysis of data from the ATTRACT trial, published in the Journal of Vascular Surgery: Venous and Lymphatic Disorders (JVSVL), has revealed that quality...
PTS

New ATTRACT data show catheter-based therapy significantly reduces leg symptoms and...

A new study, recently published online in the journal Circulation, reports on outcomes from a subgroup of 391 patients with acute iliofemoral deep venous...

ACCESS PTS study demonstrates Ekos’ efficacy in treatment of post-thrombotic syndrome

BTG has highlighted the results of the ACCESS PTS trial, presented at the Society for Vascular Medicine 28th annual scientific sessions (14–17 June, New...

ATTRACT fails to meet primary endpoint, but experts agree results are...

Data from the randomised controlled ATTRACT trial revealed that the addition of catheter-based intervention to standard-of-care anticoagulation failed to significantly decrease the occurrence of...